A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants with Thyroid Eye Disease

Is This Study For You?

Let's Get Started!

Description

The purpose of this dose ranging study is to study the efficacy and safety of TOUR006 SC compared with placebo in participants with moderate to severe TED.

Details
Age
Adult
Eligibility
Male and female participants, from 18 to 75 years of age inclusive, with moderate to severe TED.
Locations

University of Colorado Hospital

Principal Investigator
Photograph of Prem Subramanian

Prem Subramanian

Study ID

Protocol Number: 23-1181

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers